M88 game APK Assists Livzon MabPharm, Inc. and Bright Peak to enter into a research cooperation and technology license agreement regarding Antibody–Drug Conjugates (ADCs)

On November 15th 2021, Bright Peak Therapeutics (“Bright Peak”) M88 game APK Livzon MabPharm, Inc. (“Livzon MabPharm”), the holding subsidiary of Livzon Pharmaceutical Group Inc. (A-share code: 000513, Hong Kong share code: 01513) (“Livzon Group”), announced that they had signed a research cooperation M88 game APK technology license agreement. Livzon MabPharm licensed its recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection to Bright Peak in the form of paid non-exclusive rights for the development of new PD-1 targeted immune cytokines (PD-1 ICs), M88 game APK licensed Bright Peak to use LZM009 for the development M88 game APK commercialization of PD-1 ICs drugs worldwide (except in Greater China).

Livzon MabPharm is a holding subsidiary of Livzon Group, specializing in the R & D of innovative antibody drugs, fusion / recombinant protein drugs M88 game APK other new biological agents used in immuno-oncology M88 game APK reproductive M88 game APK autoimmune diseases.

Bright peak is a private biotechnology company with headquarters in San Diego M88 game APK Basel, SwitzerlM88 game APK. It is committed to creating the next generation of cytokine immunotherapy for patients with cancer M88 game APK autoimmune diseases.

M88 game APK was entrusted by Livzon Group to review, modify and negotiate the transaction documents. As a comprehensive law firm with long-term experience in patent and business law across China and the United States, M88 game APK provides its clients with high-quality, rigorous and efficient professional legal services throughout the transaction process.

This project was led by partners Mr. Li, Qi (Adam) M88 game APK Mr.m88 sport betting.